Does Semaglutide Cause Stomach Problems?

The week your pen arrives and you take the first dose

Picture it: a plain, unbranded box appears on your doorstep, tracked by DPD. Inside is your Wegovy pen. You inject the starter dose (0.25mg) and wait. For some people, nothing much happens. For others, a mild queasiness arrives later that day or the next morning, often strongest around mealtimes. This is normal, and it is by design.

Semaglutide acts on GLP-1 receptors in the gut as well as the brain. One of its direct effects is delayed gastric emptying: food stays in the stomach longer than usual. That slowing is part of why appetite falls, but it also means the stomach is processing a backlog, and that produces the bloating, fullness, nausea and occasional vomiting that patients most commonly describe. The Wegovy treatment page gives a fuller picture of how the medicine works and what the licensed programme involves.

The good news is that the starter dose is designed specifically to limit this. At 0.25mg, the body is being introduced gently to the medicine, not treated with it at full therapeutic strength. Most people find the GI effects are most noticeable in the first one to two weeks of each dose level, then settle. Eating smaller portions, avoiding very fatty meals, and not lying down immediately after eating all reduce the severity. None of that is a cure, but taken together it makes the adjustment period more manageable.

The symptoms that are common versus the ones that need a call to 111

The NHS medicines information for semaglutide lists the most frequent gastrointestinal complaints clearly: nausea, vomiting, diarrhoea, constipation, indigestion, acid reflux and burping. Fatigue and headache also feature. These are unpleasant, but they are not dangerous in themselves for most people, and they tend to follow the pattern above: peaking at a dose increase, then fading.

Dehydration is the practical risk that catches people out. Repeated vomiting or diarrhoea means fluid loss, and if you cannot keep fluids down for more than a day or two, kidney function can be affected. Drink small amounts frequently rather than large quantities at once.

There are symptoms that sit in a different category entirely. The MHRA issued a Drug Safety Update in January 2026 specifically addressing acute pancreatitis as a known, though infrequent, risk with GLP-1 medicines including semaglutide. The signal to act urgently is severe stomach pain that persists and spreads to the back, with or without vomiting. That combination is not a normal nausea episode. Stop eating, stop the injection, and get medical help the same day, call 111 or go to A&E if the pain is severe. Gallbladder problems, which can produce sharp pain in the upper right abdomen, are a separate but related consideration worth knowing about. The broader overview of reported semaglutide problems covers these and other system effects in more detail.

Yellow Card, the MHRA's reporting tool at yellowcard.mhra.gov.uk, is there for patients who want to formally report a side effect. It contributes to the post-market safety picture for these medicines.

Does it get better, or does it stay this bad?

For the majority of people, yes, it does get better. The STEP 1 clinical trial, published in the New England Journal of Medicine, recorded that gastrointestinal side effects were most common but that most were mild to moderate and transient. Discontinuation due to GI adverse events happened in a minority of participants, not the majority.

The titration schedule matters here. Semaglutide doses step up roughly every four weeks, and each step can temporarily revive symptoms that had settled. Patients who find a particular dose level very difficult can discuss with their prescriber whether to extend the time at that dose before moving up. That is a clinical conversation, not something to manage alone. The num FAQ page addresses some of the practical questions that come up around this.

Some stomach symptoms do persist beyond the initial weeks for a minority of people. Persistent constipation, for instance, can linger through the maintenance phase and may need dietary adjustment, increased fibre, adequate hydration, regular movement. A prescriber or dietitian can advise on what is realistic alongside treatment.

It is also worth noting that not all stomach problems on semaglutide are caused by semaglutide. Interactions with other medicines taken at the same time, the timing of doses relative to food, and underlying digestive conditions can all play a role. If you take other regular medicines, it is worth checking whether timing matters. The page on metronidazole and semaglutide is one example of a specific interaction question our prescribers are asked regularly.

How this affects whether semaglutide is right for you

Stomach problems alone do not disqualify someone from treatment. They are part of the known profile of the medicine, weighed against its clinical benefits for weight management. The NHS's guidance on semaglutide covers side effects in plain language and is worth reading in full before you start.

What matters is whether the side effects are manageable, whether there are contraindications that make GI risks higher for a specific person, and whether the dose titration can be adjusted if needed. None of those assessments can be made from a webpage. They are the conversation that happens during clinical review.

If you are already on treatment and finding stomach problems disruptive, the right move is to contact your prescriber rather than stopping abruptly. If you are considering semaglutide and want to understand your suitability before anything else, the free consultation with our GPhC-registered prescribers is where that conversation starts. There are also related questions on things like sleep disturbance during Wegovy treatment that can be worth reviewing alongside the GI profile, and patients sometimes ask about whether Wegovy can cause vision problems, since the side-effect picture is broader than just the digestive system. Check your eligibility and speak to a real clinician before you decide.